Tenaya Therapeutics (TNYA) and its competitors face to face Contrast


Therapeutic Tenaya (NASDAQ:TNYAGet a rating) is one of 257 SOEs in the Biologics, Except Diagnostics sector, but how does it stack up against its peers? We will compare Tenaya Therapeutics to similar companies based on the strength of its profitability, analyst recommendations, valuation, risk, earnings, institutional ownership and dividends.

Institutional and insider ownership

83.4% of Tenaya Therapeutics shares are held by institutional investors. In comparison, 53.3% of the shares of all “Biologicals, except diagnostics” companies are held by institutional investors. 16.4% of the shares of all Biologics excluding Diagnostics companies are held by insiders. Strong institutional ownership indicates that large fund managers, hedge funds, and endowments believe a company will outperform the market over the long term.

Valuation and benefits

This table compares the revenue, earnings per share (EPS), and valuation of Tenaya Therapeutics and its peers.

Gross revenue Net revenue Price/earnings ratio
Therapeutic Tenaya N / A -72.72 million dollars -0.43
Competitors of Tenaya Therapeutics $773.46 million $147.16 million 0.05

Tenaya Therapeutics peers have higher revenue and profit than Tenaya Therapeutics. Tenaya Therapeutics trades at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


This table compares the net margins, return on equity, and return on assets of Tenaya Therapeutics and its peers.

Net margins Return on equity return on assets
Therapeutic Tenaya N / A -50.18% -33.45%
Competitors of Tenaya Therapeutics -4,587.78% -67.40% -30.70%

Analyst Notes

This is a breakdown of current recommendations and price targets for Tenaya Therapeutics and its peers, as provided by MarketBeat.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
Therapeutic Tenaya 0 0 4 0 3.00
Competitors of Tenaya Therapeutics 1675 5782 11417 210 2.53

Tenaya Therapeutics currently has a consensus target price of $36.00, suggesting a potential upside of 444.63%. As a group, the “Biologicals, excluding diagnostics” companies have an upside potential of 107.40%. Given Tenaya Therapeutics’ higher consensus rating and higher upside potential, research analysts clearly believe that Tenaya Therapeutics is more favorable than its peers.


Tenaya Therapeutics beats its peers on 6 of the 11 factors compared.

Tenaya Therapeutics Company Profile (Get a rating)

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops and delivers therapies for heart disease in the United States. It develops its products via cell regeneration, gene therapy and precision medicine platforms. The Company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to treat genetic hypertrophic cardiomyopathy (gHCM) caused by mutations in the haploinsufficient myosin binding protein C3 (MYBPC3) gene; and TN-301, a small molecule histone deacetylase 6 (HDAC6i) inhibitor for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that treats genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by mutations in the plakophilin 2 (PKP2) gene; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene into the heart for DCM; and the Reprogramming Program, an AAV-based approach to heart regeneration to replace lost heart cells in patients with heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Get news and reviews for Tenaya Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Tenaya Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.


Comments are closed.